ZSZeeshan Sidiq

Zeeshan Sidiq

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zeeshan Sidiq has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open-platform real-time PCR for Tuberculosis in India: From diagnostic validation to strategic integration

    by Zeeshan Sidiq, Ankita Anand, Kaushal Kumar Dwivedi, Sanjay Rajpal, Kamal Kishore Chopra

  • Open Access

    Analytical performance of a multi-target open real-time PCR assay for simultaneous detection of tuberculosis, non-tuberculous mycobacteria, and drug resistance in a high-burden setting

    by Zeeshan Sidiq, Ankita Anand, Payal Tyagi, Kaushal Kumar Dwivedi, Sanjay Rajpal, Kamal Kishore Chopra

    Timely diagnosis of tuberculosis (TB) and drug resistance is crucial for effective disease control. Multiplex open molecular platforms capable of simultaneously detecting Mycobacterium tuberculosis complex (MTBc), non-tuberculous mycobacteria (NTM), and resistance to first-line anti-TB drugs could significantly streamline diagnostic pathways. We evaluated two multiplex real-time PCR assays (MTBc/NTM R-Gene and MTB-RIF/INH R-Gene) using 300 well-characterized samples (150 MTBc-positive and 150 MTBc-negative). Composite reference standards, including culture, MPT64 antigen testing, and line probe assays and phenotypic drug susceptibility testing. The MTBc detection demonstrated 100% sensitivity and specificity (150/150). NTM detection showed 70.0% sensitivity (35/50) and 100% specificity, indicating limitations in NTM species coverage. Rifampicin resistance was detected with 96.0% sensitivity (48/50) and 100% specificity. Isoniazid resistance detection achieved 100% sensitivity and specificity (50/50). High agreement (κ = 0.76–1.00) with established reference standards was observed. This analytical validation confirms that multiplex open real-time PCR assays accurately and simultaneously detect MTBc, NTM, and rifampicin and isoniazid resistance using culture isolates. Clinical validation is warranted. While these platforms offer potential advantages in flexibility and expanded resistance profiling, further studies on clinical diagnostic accuracy, cost-effectiveness, and operational feasibility are essential to determine their practical utility and programmatic impact in high-burden settings. IMPORTANCE: Despite major advances in molecular diagnostics, critical gaps persist in tuberculosis (TB) detection, particularly the limited identification of isoniazid resistance and inadequate differentiation from non-tuberculous mycobacteria. In this study, a multiplex open real-time PCR assay demonstrated high analytical accuracy for simultaneous detection of Mycobacterium tuberculosis complex, rifampicin and isoniazid resistance, with strong agreement to reference standards. By integrating multi-target detection within a single workflow, this approach addresses key limitations of current diagnostic strategies that rely on rifampicin as a surrogate for multidrug resistance. The open-platform design further offers flexibility, scalability, and reduced dependence on proprietary systems, which are critical considerations in high-burden settings. These findings highlight the potential of next-generation molecular diagnostics to improve early resistance detection, refine treatment decisions, and strengthen TB control efforts globally.


  • Open Access

    Diagnostic accuracy, operational feasibility, and cost considerations of Truenat MTB Plus and Xpert MTB/RIF Ultra for pulmonary tuberculosis

    by Zeeshan Sidiq, Ankita Anand, Kaushal Kumar Dwivedi, Payal Tyagi, Sanjay Rajpal, Kamal Kishore Chopra, Shikha Dhawan, Vishal Khanna

    Background: Tuberculosis (TB) remains a major global health challenge, necessitating rapid and accurate diagnostic tools. The World Health Organization (WHO) endorses nucleic acid amplification tests (NAATs) like Truenat MTB Plus and Xpert MTB/RIF Ultra. While both are widely implemented, direct comparisons integrating diagnostic accuracy with operational and cost considerations across real-world settings are limited. This study aimed to compare the diagnostic accuracy of Truenat MTB Plus and Xpert MTB/RIF Ultra for the detection of Mycobacterium tuberculosis (MTB) and rifampicin resistance (RIF-R) among presumptive pulmonary TB patients in India, while also assessing their operational feasibility and cost-related parameters. Methods: This prospective diagnostic accuracy study was conducted at New Delhi Tuberculosis Centre, in New Delhi, India, enrolling 664 presumptive pulmonary TB patients. Paired sputum specimens were tested using Truenat MTB Plus/MTB-RIF and Xpert MTB/RIF Ultra. Mycobacterial culture was used as the primary reference standard for MTB detection, and phenotypic drug susceptibility testing (pDST) was used for RIF-R detection. Sensitivity, specificity, and overall accuracy were calculated, and operational parameters, including invalid/indeterminate rates and cost per test, were recorded. Results: The overall prevalence of culture-confirmed TB was 14.8% (98/664), with a RIF-R prevalence of 7.1% (7/98). Compared with culture, Xpert MTB/RIF Ultra demonstrated a sensitivity of 97.9% (95% CI: 95.2–100%) and a specificity of 95.5% (95% CI: 93.7–97.3%). Truenat MTB Plus showed a sensitivity of 92.5% (95% CI: 85.1–96.6%) and a specificity of 90.1% (95% CI: 86.8–92.6%). For RIF-R detection, Xpert Ultra had a sensitivity of 83.3% and a specificity of 100%, compared to Truenat MTB-RIF’s sensitivity of 75.0% and specificity of 100%. Operationally, Truenat had a significantly higher rate of invalid results (5.9% vs 0%) and RIF indeterminate results (46.5% vs 13.2%) compared to Xpert Ultra, resulting in an increased need for repeat testing. The cost per test was lower for Truenat (approximately INR 800 for MTB Plus) compared to Xpert MTB/RIF Ultra (approximately INR 1800). Conclusion: Both Truenat MTB Plus and Xpert MTB/RIF Ultra demonstrated excellent diagnostic accuracy for TB detection. Xpert Ultra showed superior accuracy and lower indeterminate rates, while Truenat offers substantial operational and cost advantages for decentralized deployment; however, higher rates of invalid and indeterminate results may increase operational burden due to repeat testing. These findings support a tiered diagnostic approach, leveraging the strengths of both platforms to expand molecular testing access and accelerate progress toward global TB elimination goals.

  • Open Access

    Analytical performance of a multi-target open real-time PCR assay for simultaneous detection of tuberculosis, non-tuberculous mycobacteria, and drug resistance in a high-burden setting

    by Zeeshan Sidiq, Payal Tyagi, Ankita Anand, Kaushal Kumar Dwivedi, Sanjay Rajpal, Kamal Kishore Chopra

    Background: Timely diagnosis of tuberculosis and drug resistance remains a cornerstone of effective disease control. Multiplex open molecular platforms capable of simultaneously detecting Mycobacterium tuberculosis complex (MTBc), non-tuberculous mycobacteria (NTM), and resistance to first-line anti-tuberculosis drugs could streamline diagnostic pathways. Methods: We conducted a laboratory-based evaluation of two multiplex real-time PCR assays (MTBc/NTM R-Gene® and MTB-RIF/INH R-Gene®) using 300 well-characterized samples, including 150 MTBc-positive culture isolates (including rifampicin-resistant, isoniazid-resistant, and drug-susceptible strains) and 150 MTBc-negative samples (50 NTM isolates and 100 mycobacteria-negative specimens). Composite reference standards included culture, MPT64 antigen testing, and line probe assay corroborated by phenotypic drug susceptibility testing for resistance profiling, with NTM speciation performed using a dedicated line probe assay. DNA extraction was performed using the QIAamp DNA Mini Kit (QIAGEN, Germany), followed by amplification on a real-time PCR platform according to manufacturer instructions. The diagnostic performance was assessed against composite reference standards. Results: The analytical performance for detecting MTBc demonstrated 100% sensitivity and specificity (150/150). NTM detection showed 70·0% sensitivity (35/50) and a specificity of 100%, highlighting limitations in coverage of NTM species. Rifampicin resistance was detected with a sensitivity of 96·0% (48/50) and specificity of 100%, whereas isoniazid resistance detection was 100% sensitive and specific (50/50). Agreement with established reference standards was high (κ=0·76–1·00) within this analytical context. Interpretation: This analytical validation demonstrates that multiplex open real-time PCR assays can accurately and simultaneously detect MTBc, NTM, and rifampicin and isoniazid resistance using culture isolates. While these platforms offer potential advantages in flexibility and expanded resistance profiling, additional studies on clinical diagnostic accuracy, cost-effectiveness analyses, and operational feasibility are required to determine their practical utility and programmatic impact in high-burden settings

  • Open Access

    Diagnostic accuracy, operational feasibility, and cost considerations of Truenat MTB Plus and Xpert MTB/RIF Ultra for pulmonary tuberculosis

    by Zeeshan Sidiq, Ankita Anand, Kaushal Kumar Dwivedi, Payal Kumar Tyagi, Sanjay Kumar Rajpal, Kamal Kishore Chopra, Shikha Dhawan, Vishal Khanna

    Background: Tuberculosis (TB) remains a major global health challenge, necessitating rapid and accurate diagnostic tools. The World Health Organization (WHO) endorses nucleic acid amplification tests (NAATs) like Truenat MTB Plus and Xpert MTB/RIF Ultra. While both are widely implemented, direct comparisons integrating diagnostic accuracy with operational and cost considerations across real-world settings are limited. This study aimed to compare the diagnostic accuracy of Truenat MTB Plus and Xpert MTB/RIF Ultra for the detection of Mycobacterium tuberculosis (MTB) and rifampicin resistance (RIF-R) among presumptive pulmonary TB patients in India, while also assessing their operational feasibility and cost-related parameters. Methods: This prospective diagnostic accuracy study was conducted at New Delhi Tuberculosis Centre, in New Delhi, India, enrolling 664 presumptive pulmonary TB patients. Paired sputum specimens were tested using Truenat MTB Plus/MTB-RIF and Xpert MTB/RIF Ultra. Mycobacterial culture was used as the primary reference standard for MTB detection, and phenotypic drug susceptibility testing (pDST) was used for RIF-R detection. Sensitivity, specificity, and overall accuracy were calculated, and operational parameters, including invalid/indeterminate rates and cost per test, were recorded. Results: The overall prevalence of culture-confirmed TB was 14.8% (98/664), with a RIF-R prevalence of 7.1% (7/98). Compared with culture, Xpert MTB/RIF Ultra demonstrated a sensitivity of 97.9% (95% CI: 95.2–100%) and a specificity of 95.5% (95% CI: 93.7–97.3%). Truenat MTB Plus showed a sensitivity of 92.5% (95% CI: 85.1–96.6%) and a specificity of 90.1% (95% CI: 86.8–92.6%). For RIF-R detection, Xpert Ultra had a sensitivity of 83.3% and a specificity of 100%, compared to Truenat MTB-RIF’s sensitivity of 75.0% and specificity of 100%. Operationally, Truenat had a significantly higher rate of invalid results (5.9% vs 0%) and RIF indeterminate results (46.5% vs 13.2%) compared to Xpert Ultra. However, the cost per test for Truenat was substantially lower (approx. INR 800 for MTB Plus vs INR 1800 for Ultra). Truenat’s minimal infrastructure requirements make it highly suitable for peripheral and district-level decentralized testing, while Xpert Ultra is better suited for district and reference laboratories. Conclusion: Both Truenat MTB Plus and Xpert MTB/RIF Ultra demonstrated excellent diagnostic accuracy for TB detection, significantly outperforming smear microscopy. Xpert Ultra showed superior accuracy and lower indeterminate rates, but Truenat offers substantial operational and cost advantages for decentralized deployment. These findings support a tiered diagnostic approach, leveraging the strengths of both platforms to expand molecular testing access and accelerate progress toward global TB elimination goals.

  • MDR TB: New drugs, research and policy

    by V.K. Arora, Kamal Kishore Chopra, Sanjay Rajpal, Zeeshan Sidiq

  • Open Access

    Diagnostic accuracy, operational feasibility, and cost considerations of Truenat MTB Plus and Xpert MTB/RIF Ultra for pulmonary tuberculosis

    by Zeeshan Sidiq, Ankita Anand, Kaushal Kumar Dwivedi, Payal Tyagi, Sanjay Rajpal, Kamal Kishore Chopra, Shikha Dhawan, Vishal Khanna